STAT Plus Theyre the next new thing in cancer immunotherapy but will bispecifics help more patients than CARTs

STAT Plus: They’re the next new thing in cancer immunotherapy, but will bispecifics help more patients than CAR-Ts?

Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer immunotherapy: bispecific antibodies.

More From BioPortfolio on "STAT Plus: They’re the next new thing in cancer immunotherapy, but will bispecifics help more patients than CAR-Ts?"